Report cover image

Global Benign Prostatic Hyperplasia (BPH) Medication Market Research Report 2026(Status and Outlook)

Publisher Bosson Research
Published Mar 08, 2026
Length 200 Pages
SKU # BOSS21071815

Description

Report Overview

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man""s life. BPH most often occurs during this second growth phase.The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

The global Benign Prostatic Hyperplasia (BPH) Medication market size was estimated at USD 3566.0 million in 2025 and is projected to grow at a compound annual growth rate (CAGR) of 3.40% during the forecast period.

This report offers a comprehensive and in-depth analysis of the global Benign Prostatic Hyperplasia (BPH) Medication market, covering all critical facets from a broad macroeconomic overview to detailed micro-level insights. It examines market size, competitive landscape, emerging development trends, niche segments, key drivers and challenges, as well as conducts SWOT and value chain analyses.

The insights provided enable readers to understand the competitive dynamics within the industry and formulate effective strategies to enhance profitability and market positioning. Additionally, the report presents a clear framework for evaluating the current status and future outlook of business organizations operating in this sector.

A significant focus of this report lies in the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Medication market. It offers detailed profiles of major players, including their market shares, performance metrics, product portfolios, and operational status. This enables stakeholders to identify leading competitors and gain a nuanced understanding of market rivalry and structure.

In summary, this report serves as an essential resource for industry participants, investors, researchers, consultants, and business strategists, as well as anyone planning to enter or expand their presence in the Benign Prostatic Hyperplasia (BPH) Medication market.

Global Benign Prostatic Hyperplasia (BPH) Medication Market: Market Segmentation Analysis

This research report provides a detailed segmentation of the market by region (country), key manufacturers, product type, and application. Market segmentation divides the overall market into distinct subsets based on factors such as product categories, end-user industries, geographic locations, and other relevant criteria.

A clear understanding of these market segments enables decision-makers to tailor their product development, sales, and marketing strategies more effectively to meet the unique needs of each segment. Leveraging market segmentation insights can significantly enhance targeted approaches, optimize resource allocation, and accelerate product innovation cycles by aligning offerings with the specific demands of diverse customer groups.

Key Company

Astellas Pharma

Eli Lilly

GlaxoSmithKline

Sanofi

ADC Therapeutics

Bayer HealthCare

Bristol-Myers Squibb

Valeant Pharmaceuticals

Endo Pharmaceuticals

Foresee Pharmaceuticals

Merck

Novartis

Advaxis

Teva Pharmaceutical Industries

Urologixs

Agennix

ANI Pharmaceuticals

BHR Pharma

Boehringer Ingelheim

Sanpower Group

Eisai

Ferring

IO THERAPEUTICS

LIDDS

Madrigal Pharmaceuticals

Nymox Pharmaceutical

Spectrum Pharmaceuticals

Takeda Pharmaceuticals

Market Segmentation (by Type)

5-Alpha-Reductase Inhibitors

Beta-Blockers

Botanicals and Traditional Chinese Medicine

Market Segmentation (by Application)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Geographic Segmentation

North America (USA, Canada, Mexico)

Europe (Germany, UK, France, Russia, Italy, Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)

South America (Brazil, Argentina, Columbia, Rest of South America)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Key Benefits of This Market Research:

Industry drivers, restraints, and opportunities covered in the study

Neutral perspective on the market performance

Recent industry trends and developments

Competitive landscape & strategies of key players

Potential & niche segments and regions exhibiting promising growth covered

Historical, current, and projected market size, in terms of value

In-depth analysis of the Benign Prostatic Hyperplasia (BPH) Medication Market

Overview of the regional outlook of the Benign Prostatic Hyperplasia (BPH) Medication Market:

Chapter Outline

Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.

Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Benign Prostatic Hyperplasia (BPH) Medication Market and its likely evolution in the short to mid-term, and long term.

Chapter 3 makes a detailed analysis of the market's competitive landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.

Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porter's five forces analysis.

Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 9 shares the main producing countries of Benign Prostatic Hyperplasia (BPH) Medication, their output value, profit level, regional supply, production capacity layout, etc. from the supply side.

Chapter 10 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.

Chapter 11 provides a quantitative analysis of the market size and development potential of each region in the next five years.

Chapter 12 provides a quantitative analysis of the market size and development potential of each market segment in the next five years.

Chapter 13 is the main points and conclusions of the report.

Key Reasons to Buy this Report:

Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change

This enables you to anticipate market changes to remain ahead of your competitors

You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents

The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly

Provision of market value data for each segment and sub-segment

Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market

Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region

Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled

Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players

The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions

Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis

Provides insight into the market through Value Chain

Market dynamics scenario, along with growth opportunities of the market in the years to come

Table of Contents

200 Pages
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Benign Prostatic Hyperplasia (BPH) Medication
1.2 Key Market Segments
1.2.1 Benign Prostatic Hyperplasia (BPH) Medication Segment by Type
1.2.2 Benign Prostatic Hyperplasia (BPH) Medication Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Benign Prostatic Hyperplasia (BPH) Medication Market Overview
2.1 Global Market Overview
2.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size (M USD) Estimates and Forecasts (2020-2035)
2.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Estimates and Forecasts (2020-2035)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Landscape
3.1 Company Assessment Quadrant
3.2 Global Benign Prostatic Hyperplasia (BPH) Medication Product Life Cycle
3.3 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Manufacturers (2020-2025)
3.4 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Manufacturers (2020-2025)
3.5 Benign Prostatic Hyperplasia (BPH) Medication Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Benign Prostatic Hyperplasia (BPH) Medication Average Price by Manufacturers (2020-2025)
3.7 Manufacturers’ Manufacturing Sites, Areas Served, and Product Types
3.8 Benign Prostatic Hyperplasia (BPH) Medication Market Competitive Situation and Trends
3.8.1 Benign Prostatic Hyperplasia (BPH) Medication Market Concentration Rate
3.8.2 Global 5 and 10 Largest Benign Prostatic Hyperplasia (BPH) Medication Players Market Share by Revenue
3.8.3 Mergers & Acquisitions, Expansion
4 Benign Prostatic Hyperplasia (BPH) Medication Industry Chain Analysis
4.1 Benign Prostatic Hyperplasia (BPH) Medication Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Benign Prostatic Hyperplasia (BPH) Medication Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Industry News
5.4.1 New Product Developments
5.4.2 Mergers & Acquisitions
5.4.3 Expansions
5.4.4 Collaboration/Supply Contracts
5.5 PEST Analysis
5.5.1 Industry Policies Analysis
5.5.2 Economic Environment Analysis
5.5.3 Social Environment Analysis
5.5.4 Technological Environment Analysis
5.6 Global Benign Prostatic Hyperplasia (BPH) Medication Market Porter's Five Forces Analysis
5.6.1 Global Trade Frictions
5.6.2 U.S. Tariff Policy – April 2025
5.6.3 Global Trade Frictions and Their Impacts to Benign Prostatic Hyperplasia (BPH) Medication Market
5.7 ESG Ratings of Leading Companies
6 Benign Prostatic Hyperplasia (BPH) Medication Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Type (2020-2025)
6.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Type (2020-2025)
6.4 Global Benign Prostatic Hyperplasia (BPH) Medication Price by Type (2020-2025)
7 Benign Prostatic Hyperplasia (BPH) Medication Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Sales by Application (2020-2025)
7.3 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size (M USD) by Application (2020-2025)
7.4 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Growth Rate by Application (2020-2025)
8 Benign Prostatic Hyperplasia (BPH) Medication Market Sales by Region
8.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
8.1.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
8.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Sales Market Share by Region
8.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
8.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
8.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
8.3 North America
8.3.1 North America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
8.3.2 North America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
8.3.3 U.S. Market Overview
8.3.4 Canada Market Overview
8.3.5 Mexico Market Overview
8.4 Europe
8.4.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
8.4.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
8.4.3 Germany Market Overview
8.4.4 France Market Overview
8.4.5 U.K. Market Overview
8.4.6 Italy Market Overview
8.4.7 Spain Market Overview
8.5 Asia Pacific
8.5.1 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
8.5.2 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
8.5.3 China Market Overview
8.5.4 Japan Market Overview
8.5.5 South Korea Market Overview
8.5.6 India Market Overview
8.5.7 Southeast Asia Market Overview
8.6 South America
8.6.1 South America Benign Prostatic Hyperplasia (BPH) Medication Sales by Country
8.6.2 South America Benign Prostatic Hyperplasia (BPH) Medication Market Size by Country
8.6.3 Brazil Market Overview
8.6.4 Argentina Market Overview
8.6.5 Columbia Market Overview
8.7 Middle East and Africa
8.7.1 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Sales by Region
8.7.2 Middle East and Africa Benign Prostatic Hyperplasia (BPH) Medication Market Size by Region
8.7.3 Saudi Arabia Market Overview
8.7.4 UAE Market Overview
8.7.5 Egypt Market Overview
8.7.6 Nigeria Market Overview
8.7.7 South Africa Market Overview
9 Benign Prostatic Hyperplasia (BPH) Medication Market Production by Region
9.1 Global Production of Benign Prostatic Hyperplasia (BPH) Medication by Region(2020-2025)
9.2 Global Benign Prostatic Hyperplasia (BPH) Medication Revenue Market Share by Region (2020-2025)
9.3 Global Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
9.4 North America Benign Prostatic Hyperplasia (BPH) Medication Production
9.4.1 North America Benign Prostatic Hyperplasia (BPH) Medication Production Growth Rate (2020-2025)
9.4.2 North America Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
9.5 Europe Benign Prostatic Hyperplasia (BPH) Medication Production
9.5.1 Europe Benign Prostatic Hyperplasia (BPH) Medication Production Growth Rate (2020-2025)
9.5.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
9.6 Japan Benign Prostatic Hyperplasia (BPH) Medication Production (2020-2025)
9.6.1 Japan Benign Prostatic Hyperplasia (BPH) Medication Production Growth Rate (2020-2025)
9.6.2 Japan Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
9.7 China Benign Prostatic Hyperplasia (BPH) Medication Production (2020-2025)
9.7.1 China Benign Prostatic Hyperplasia (BPH) Medication Production Growth Rate (2020-2025)
9.7.2 China Benign Prostatic Hyperplasia (BPH) Medication Production, Revenue, Price and Gross Margin (2020-2025)
10 Key Companies Profile
10.1 Astellas Pharma
10.1.1 Astellas Pharma Basic Information
10.1.2 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.1.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.1.4 Astellas Pharma Business Overview
10.1.5 Astellas Pharma SWOT Analysis
10.1.6 Astellas Pharma Recent Developments
10.2 Eli Lilly
10.2.1 Eli Lilly Basic Information
10.2.2 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.2.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.2.4 Eli Lilly Business Overview
10.2.5 Eli Lilly SWOT Analysis
10.2.6 Eli Lilly Recent Developments
10.3 GlaxoSmithKline
10.3.1 GlaxoSmithKline Basic Information
10.3.2 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.3.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.3.4 GlaxoSmithKline Business Overview
10.3.5 GlaxoSmithKline SWOT Analysis
10.3.6 GlaxoSmithKline Recent Developments
10.4 Sanofi
10.4.1 Sanofi Basic Information
10.4.2 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.4.4 Sanofi Business Overview
10.4.5 Sanofi Recent Developments
10.5 ADC Therapeutics
10.5.1 ADC Therapeutics Basic Information
10.5.2 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.5.3 ADC Therapeutics Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.5.4 ADC Therapeutics Business Overview
10.5.5 ADC Therapeutics Recent Developments
10.6 Bayer HealthCare
10.6.1 Bayer HealthCare Basic Information
10.6.2 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.6.3 Bayer HealthCare Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.6.4 Bayer HealthCare Business Overview
10.6.5 Bayer HealthCare Recent Developments
10.7 Bristol-Myers Squibb
10.7.1 Bristol-Myers Squibb Basic Information
10.7.2 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.7.3 Bristol-Myers Squibb Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.7.4 Bristol-Myers Squibb Business Overview
10.7.5 Bristol-Myers Squibb Recent Developments
10.8 Valeant Pharmaceuticals
10.8.1 Valeant Pharmaceuticals Basic Information
10.8.2 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.8.3 Valeant Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.8.4 Valeant Pharmaceuticals Business Overview
10.8.5 Valeant Pharmaceuticals Recent Developments
10.9 Endo Pharmaceuticals
10.9.1 Endo Pharmaceuticals Basic Information
10.9.2 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.9.3 Endo Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.9.4 Endo Pharmaceuticals Business Overview
10.9.5 Endo Pharmaceuticals Recent Developments
10.10 Foresee Pharmaceuticals
10.10.1 Foresee Pharmaceuticals Basic Information
10.10.2 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.10.3 Foresee Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.10.4 Foresee Pharmaceuticals Business Overview
10.10.5 Foresee Pharmaceuticals Recent Developments
10.11 Merck
10.11.1 Merck Basic Information
10.11.2 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.11.3 Merck Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.11.4 Merck Business Overview
10.11.5 Merck Recent Developments
10.12 Novartis
10.12.1 Novartis Basic Information
10.12.2 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.12.3 Novartis Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.12.4 Novartis Business Overview
10.12.5 Novartis Recent Developments
10.13 Advaxis
10.13.1 Advaxis Basic Information
10.13.2 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.13.3 Advaxis Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.13.4 Advaxis Business Overview
10.13.5 Advaxis Recent Developments
10.14 Teva Pharmaceutical Industries
10.14.1 Teva Pharmaceutical Industries Basic Information
10.14.2 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.14.3 Teva Pharmaceutical Industries Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.14.4 Teva Pharmaceutical Industries Business Overview
10.14.5 Teva Pharmaceutical Industries Recent Developments
10.15 Urologixs
10.15.1 Urologixs Basic Information
10.15.2 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.15.3 Urologixs Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.15.4 Urologixs Business Overview
10.15.5 Urologixs Recent Developments
10.16 Agennix
10.16.1 Agennix Basic Information
10.16.2 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.16.3 Agennix Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.16.4 Agennix Business Overview
10.16.5 Agennix Recent Developments
10.17 ANI Pharmaceuticals
10.17.1 ANI Pharmaceuticals Basic Information
10.17.2 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.17.3 ANI Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.17.4 ANI Pharmaceuticals Business Overview
10.17.5 ANI Pharmaceuticals Recent Developments
10.18 BHR Pharma
10.18.1 BHR Pharma Basic Information
10.18.2 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.18.3 BHR Pharma Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.18.4 BHR Pharma Business Overview
10.18.5 BHR Pharma Recent Developments
10.19 Boehringer Ingelheim
10.19.1 Boehringer Ingelheim Basic Information
10.19.2 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.19.3 Boehringer Ingelheim Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.19.4 Boehringer Ingelheim Business Overview
10.19.5 Boehringer Ingelheim Recent Developments
10.20 Sanpower Group
10.20.1 Sanpower Group Basic Information
10.20.2 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.20.3 Sanpower Group Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.20.4 Sanpower Group Business Overview
10.20.5 Sanpower Group Recent Developments
10.21 Eisai
10.21.1 Eisai Basic Information
10.21.2 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.21.3 Eisai Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.21.4 Eisai Business Overview
10.21.5 Eisai Recent Developments
10.22 Ferring
10.22.1 Ferring Basic Information
10.22.2 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.22.3 Ferring Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.22.4 Ferring Business Overview
10.22.5 Ferring Recent Developments
10.23 IO THERAPEUTICS
10.23.1 IO THERAPEUTICS Basic Information
10.23.2 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.23.3 IO THERAPEUTICS Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.23.4 IO THERAPEUTICS Business Overview
10.23.5 IO THERAPEUTICS Recent Developments
10.24 LIDDS
10.24.1 LIDDS Basic Information
10.24.2 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.24.3 LIDDS Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.24.4 LIDDS Business Overview
10.24.5 LIDDS Recent Developments
10.25 Madrigal Pharmaceuticals
10.25.1 Madrigal Pharmaceuticals Basic Information
10.25.2 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.25.3 Madrigal Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.25.4 Madrigal Pharmaceuticals Business Overview
10.25.5 Madrigal Pharmaceuticals Recent Developments
10.26 Nymox Pharmaceutical
10.26.1 Nymox Pharmaceutical Basic Information
10.26.2 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.26.3 Nymox Pharmaceutical Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.26.4 Nymox Pharmaceutical Business Overview
10.26.5 Nymox Pharmaceutical Recent Developments
10.27 Spectrum Pharmaceuticals
10.27.1 Spectrum Pharmaceuticals Basic Information
10.27.2 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.27.3 Spectrum Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.27.4 Spectrum Pharmaceuticals Business Overview
10.27.5 Spectrum Pharmaceuticals Recent Developments
10.28 Takeda Pharmaceuticals
10.28.1 Takeda Pharmaceuticals Basic Information
10.28.2 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Overview
10.28.3 Takeda Pharmaceuticals Benign Prostatic Hyperplasia (BPH) Medication Product Market Performance
10.28.4 Takeda Pharmaceuticals Business Overview
10.28.5 Takeda Pharmaceuticals Recent Developments
11 Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Region
11.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast
11.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Country
11.2.3 Asia Pacific Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Region
11.2.4 South America Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Country
12 Forecast Market by Type and by Application (2026-2035)
12.1 Global Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Type (2026-2035)
12.1.1 Global Forecasted Sales of Benign Prostatic Hyperplasia (BPH) Medication by Type (2026-2035)
12.1.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size Forecast by Type (2026-2035)
12.1.3 Global Forecasted Price of Benign Prostatic Hyperplasia (BPH) Medication by Type (2026-2035)
12.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Forecast by Application (2026-2035)
12.2.1 Global Benign Prostatic Hyperplasia (BPH) Medication Sales (K MT) Forecast by Application
12.2.2 Global Benign Prostatic Hyperplasia (BPH) Medication Market Size (M USD) Forecast by Application (2026-2035)
13 Conclusion and Key Findings
How Do Licenses Work?
Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.